Understand the source comparison
Mechanism Pathways: GH Secretagogues vs Gonadotropin-Releasing Peptides
Growth hormone-releasing peptides like GHRP-2 and MK-677 (ibutamoren) bind to ghrelin receptors in the pituitary gland, stimulating somatotroph cells to release growth hormone in pulses that mirror endogenous circadian GH secretion. Elevated GH triggers hepati
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Growth hormone-releasing peptides like GHRP-2 and MK-677 (ibutamoren) bind to ghrelin receptors in the pituitary gland, stimulating somatotroph cells to release growth hormone in pulses that mirror endogenous circadian GH secretion. Elevated GH triggers hepatic IGF-1 (insulin-like growth factor-1) production, which exerts anabolic effects across multiple tissues. Skeletal muscle, adipose, and reproductive organs. The testosterone connection is indirect: IGF-1 improves insulin sensitivity, which reduces sex hormone-binding globulin (SHBG) levels, increasing free testosterone availability. Additionally, improved body composition. Higher lean mass, lower visceral fat. Correlates with restored hypothalamic sensitivity to sex steroids, reducing the negative feedback that suppresses GnRH release in metabolically compromised individuals.
- Gonadotropin-releasing peptides like gonadorelin (synthetic GnRH) and kisspeptin analogues act directly on the hypothalamic-pituitary-gonadal axis. Gonadorelin binds to GnRH receptors on gonadotroph cells in the anterior pituitary, triggering LH and FSH release. LH binds to Leydig cell receptors in the testes, activating the enzymatic cascade that converts cholesterol into pregnenolone, then progesterone, then androstenedione, and finally testosterone via 17β-hydroxysteroid dehydrogenase. This is the same pathway exogenous testosterone replacement bypasses entirely. Gonadorelin restores it. The critical difference: gonadorelin preserves testicular function and spermatogenesis because it maintains pulsatile LH signaling, whereas continuous exogenous testosterone suppresses LH to near-zero, causing testicular atrophy and infertility.
- Our team has found that researchers selecting between these pathways often prioritize preservation of fertility and endogenous production capacity. Gonadorelin-based protocols maintain HPG axis function, while GH secretagogues support metabolic recovery that indirectly benefits androgen synthesis without directly stimulating testicular output. The trade-off: gonadorelin requires pulsatile administration (mimicking natural GnRH pulses every 90–120 minutes) to avoid receptor desensitization, while GH secretagogues can be administered once daily with sustained effect.